Загрузка...
Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial
BACKGROUND: The approval of extended release injectable naltrexone (XR-NTX; Vivitrol®) has introduced a new option for treating opioid addiction, but studies are needed to identify its place within the spectrum of available therapies. The absence of physiological opioid dependence is a necessary and...
Сохранить в:
| Главные авторы: | , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4017322/ https://ncbi.nlm.nih.gov/pubmed/24602363 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drugalcdep.2014.02.002 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|